Abstract: The invention relates to an apharesis device for use in the treatment of Alzheimer patients. Said device comprises a solid support with which a flow of blood or plasma can be contacted.

Abstract: The invention relates to a method for treating Alzheimer's disease by inducing sequestration of amyloid ? into a plasma with a A?-mimotope peptide, and treatment with an apheresis device such that a fixed carrier can come into contact with the blood or plasma flow and includes a receptor that binds to an amyloid-? precursor-protein (APP), the APP being removed from the blood with the apheresis device.

Abstract: The invention relates to an apheresis device for use in the treatment of Alzheimer patients. Said device comprises a solid support with which a flow of blood or plasma can be contacted.

Abstract: The present invention relates to the use of mimotopes in the treatment of diseases associated with ?-amyloid formation and/or aggregation (?-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to A?1-40/42, A?pE3-40/42, A?3-40/42 and A?11-40/42.

Abstract: The present invention relates to a compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (A?).

Abstract: The present invention relates to methods for preventing Alzheimer's disease (AD) with an A?42 mimotope and binds to an antibody specific for DAEFRH (SEQ ID NO: 1) which is a part of the naturally-occurring A?42 sequence.

Abstract: The present invention relates to methods for preventing and treating Alzheimer's disease (AD). An A?42 mimotope is used for vaccination against AD. The mimotope induces the production of antibodies against A?42 but not against the native APP. The mimotope is functionally similar to, but not structurally identical with DAEFRH (SEQ ID NO: 1) which is a part of the naturally-occurring A?42 sequence.

Abstract: Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

Abstract: The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1-XZXZNXZX-R2, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independently one from the other from the ?group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X-R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for enhancing a patient's adaptive immune response to an antigen.

Abstract: The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides—start with a methionine amino acid residue,—comprise an antigenic determinant and—comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.

Abstract: The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected from neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.

Abstract: The invention relates to a method and a device for commissioning articles from a first number of pick-up sections (16) into a corresponding number of order placement sections (18), by means of a second number of commissioners (20). Thus, only one commissioner (20) carries out commissioning in a commissioning zone (14), such that the number of commissioning zones (14) is the same as the second number of commissioners (20) and the commissioning computer (28) varies the boundaries (15) between adjacent commissioning zones (14) by means of a zone allocation strategy (Z) in order to match the size of the commissioning zones in the commissioning region (12) and/or the number of commissioning zones (14) in the commissioning region (12) to variable influence commissioning parameters.

Abstract: Described are methods for isolating Hepatitis C Virus peptides (HPs) that have a binding capacity to a MHC/HLA molecule or a complex comprising the HCV-peptide and the MHC/HLA molecule. In one aspect, these methods include providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex. Also described are immunogenic compositions that stimulate a specific T cell response to hepatitis C virus when administered to a subject in an effective amount.

Abstract: The invention relates to the use of a compound comprising the following amino acid sequence X1X2X3X4X5X6X7, wherein X1 is an amino acid, except of C, X2 is an amino acid, except of C, X3 is an amino acid, except of C, X4 is an amino acid, except of C, X5 is an amino acid, except of C, X6 is not present or any amino acid, X7 is not present or any amino acid, and wherein X1X2X3X4X5X6 is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal A?42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal A?42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.

Abstract: Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

Abstract: Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex.

Abstract: The invention relates to a method for preventing or treating Alzheimer's disease (AE). According to said method, a means for inducing a sequestration of amyloid ? (A?) into a plasma is administered to a person, and the person is treated by means of an apheresis device comprising a fixed carrier that can come into contact with the blood or plasma flow and comprises a receptor binding an amyloid-?-precursor-protein (APP), the APP being removed from the blood of the person by means of the apheresis device. The invention also relates to a set for carrying out said method.

Abstract: The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.

Abstract: The invention relates to a composition comprising a T cell epitope or a mixture of T cell epitopes a polycationic peptide and a nucleic acid based on inosin and cytosin and its use as a vaccine.

Abstract: The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.